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Abstract
Aim—The aim is to develop irradiated nanodiamonds (INDs) as a molecularly-targeted contrast 
agent for high resolution and phenotype-specific detection of breast cancer with photoacoustic 
(PA) imaging.
Materials & Methods—The surface of acid treated radiation-damaged nanodiamonds was 
grafted with polyethylene glycol (PEG) to improve its stability and circulation time in blood, 
followed by conjugation to an anti-Human epidermal growth factor receptor-2 (HER2) peptide 
(KCCYSL) with a final nanoparticle size of ca. 92 nm. Immunocompetent mice bearing orthotopic 
HER2 positive or negative tumors were administered INDs and PA imaged using an 820-nm near 
infrared laser.
Results—PA images demonstrated that INDs accumulate in tumors and completely delineated 
the entire tumor within 10 hours. HER2 targeting significantly enhanced imaging of HER2-
positive tumors. Pathological examination demonstrated INDs are non-toxic.
Conclusions—PA technology is adaptable to low-cost bedside medicine, and with new contrast 
agents described herein, PA can achieve high resolution (sub-mm) and phenotype specific 
monitoring of cancer growth.
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1. Introduction
Breast cancer is a leading cause of death in women, and 12% of the world’s women will 
develop breast cancer in their lifetimes, although great progress in screening and treatment 
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has been made in recent decades [1]. In approximately 25% to 30% human breast cancers, 
human epidermal growth factor receptor 2 (HER2) is overexpressed on the surface of the 
tumor cells. HER2-positive breast cancers progress rapidly, and these patients have a poor 
prognosis and lower overall survival if untreated [2]. Therefore, there is a great need to 
develop effective diagnostic techniques for early detection of HER2-positive tumors.
Photoacoustic (PA) imaging is an emerging non-invasive and non-ionizing biomedical 
imaging modality that combines the high spatial resolution of ultrasound techniques and the 
excellent contrast of optical imaging with the help of various contrast agents [3–5]. Within 
the photoacoustic effect, light is absorbed by either the tissue or exogenous agents in the 
tissue and converted to ultrasound energy via transient thermal elastic expansion. The 
attenuation of acoustic energy is 1000 times weaker than that of light in biological tissues, 
thus PA imaging has a greater penetration depth of up to several centimeters compared to 1–
2 mm for optical imaging techniques [6–9]. PA can image blood vessels, hemoglobin 
oxygenation and tumor angiogenesis with high contrast using the unique absorption spectra 
of endogenous hemoglobin and melanin [10–13]. The utilization of exogenous contrast 
agents has greatly enhanced PA imaging sensitivity and specificity, which are intrinsic 
disadvantages of traditional biomedical imaging modalities, such as computed tomography 
(CT) and ultrasound (UT) [14–17]. Organic dyes, quantum dots (QDs) and plasmonic 
nanoparticles have been used as contrast agents in PA imaging. Among these, contrast 
agents having high optical absorbance in the near-infrared (NIR) region are more attractive 
since the PA signal contribution from normal tissue and hemoglobin is minimum and the 
Mie scattering effect is relatively weak at wavelengths between 700 and 1100 nm. In 
addition to strong absorption in the NIR range, other properties of contrast agents that must 
be considered include toxicity, size, stability and surface chemistry. Some biocompatible 
dyes, including methylene blue and indocyanine green, have been used in PA imaging [18]. 
However, low molecular weight organic dyes are both non-specific in their localizations and 
are rapidly cleared from the plasma by the renal system, and fluorescent agents suffer from 
blinking and photobleaching which limit their clinical application, even though conjugation 
to nanoparticles can render them a suitable size for passive tumor uptake and retention. 
Plasmonic nanoparticles are the most developed PA contrast agents due to their tunable 
absorption and much stronger optical absorption than dyes based on the surface plasmon 
resonance (SPR) effect. Gold nanorods are used extensively in PA imaging because of their 
relatively simple synthesis, very strong SPR absorption in the NIR range, and ease of 
surface functionalization for the addition of targeting ligands [19, 20]. However, gold 
nanorods or nanobones melt and thus deform under intense laser light irradation. Although 
this strategy has been used to release DNA oligonucleotides and drugs [21, 22], gold 
nanoparticles do not provide a consistant and stable PA signal at a specific wavelength 
during the whole imaging process. In addition, the long-term toxicity of gold nanoparticles 
has to be considered in further human applications [23].
Owing to the excellent biocompatibility and exceptional optical stability, nanodiamonds 
(NDs) are an outstanding optical contrast agent and drug carrier for biomedical applications 
[24]. By introducing nitrogen vacancy centers as a fluorophor in the NDs, fluorescent 
nanodiamonds (FNDs) exhibit competitive advantages over organic fluorescent dyes and 
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QDs due to the long-term stability and low toxicity as an in vivo contrast agent [25–27]. 
Recently, alternative strategies for using nanodiamonds as imaging contrast agents have 
emerged. By making use of the detectable electron spin resonance of nitrogen-vacancy 
centers, different shapes of nanodiamond targets within chicken breast tissues were imaged 
with a spatial resolution of ca. 800 μm [28]. Carbon-dots (CDs) with tunable and strong 
photoluminescence produced by hydrothermal oxidation of nanodiamonds have been 
utilized for cell imaging [29]. Fabrication of nanodiamonds with a 
diethylenetriaminepentaacetic acid (DTPA) - Gadolinium chelate improved the signal 
intensity on T1-weighted magnetic resonance images [30].
In this work, a HER2 targeting moiety was conjugated to irradiated PEGylated NDs (PEG-
INDs) to enhance the PA imaging sensitivity and contrast of HER2-overexpressing breast 
tumors. The HER2 receptor has been employed in pre-clinical research and the clinic as a 
molecular target for breast cancer drug delivery, tumor imaging and anticancer therapy [31–
34]. However, the large size, limited stability and costs of antibodies limit the use for 
nanoparticle targeting. As a result, a six-amino acid peptide (KCCYSL) that targets HER2 
was identified using phage display technology. Peptide conjugates offer the benefits of 
simplified production, flexible conjugation on terminals and enhanced cell permeability [35–
37]. PA imaging combined with targeted INDs can provide high contrast of HER-positive 
tumors for identification of tumor growth and margins.
2. Materials and methods
2.1 Materials and Chemicals
N-(3-Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC•HCl), N-
Hydroxysuccinimide (NHS), sodium borate, sodium hydroxide, ethylenediamine tetraacetic 
acid (EDTA), adenosine 5′-diphosphate (ADP) sodium salt and potassium chloride (KCl) 
were purchased from Sigma-Aldrich (St. Louis, MO). Amine-PEG2000-amine was 
purchased from Jenkem Technology (Allen, TX). Fetal bovine serum (FBS) was purchased 
from Fisher Scientific (Pittsbrugh, PA). Dulbecco’s Modified Eagle’s Medium (DMEM) 
was purchased from Lonza (Allendale, NJ). Anti-Human epidermal growth factor receptor 2 
(anti-HER2) peptide (KCCYSL) was synthesized by conventional means [36]. 4T1.2-neu 
murine cancer cells were provided by Dr. Zhaoyang You (University of Pittsburgh, 
Pittsburgh, PA). 4T1.2 breast cancer cells were provided by Dr. Beth A. Vorderstrasse 
(Washington State University, Pullman, WA) and used with the permission of the Peter 
MacCallum Cancer Centre (East Melbourne, Australia). Deionized (DI) water was used for 
preparing all of the solutions.
2.2 Synthesis and Characterization
Natural diamond powders (type Ia) with a median size of 0.125 μm were obtained from 
Microdiamant (NAT 0–0.25). They were grounded mechanically in a tungsten carbide (WC) 
vial containing 5 WC balls (10 mm in diameter) and mounted on a high-energy shaker mill 
(8000M, SPEX) for 45 min. Particles in the size range of 35 nm were extracted by 
centrifugation from the ball-milled diamonds after cleaning in mixed aqua regia-hydrogen 
peroxide solution (1:19, v/v) gently heated to 85 °C for 1 hr, followed by extensive washes 
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with DI water [38]. The extracted 35-nm NDs were then irradiated with 40-keV He+ at a 
dose of ca. 3 × 1015 ions/cm2 [39]. After purification in concentrated H2SO4-HNO3 (3:1, 
v/v) at 100 °C in a microwave reactor for 3 hr, the He+-irradiated NDs (or called INDs) were 
thoroughly washed with DI water and stored at room temperature before use.
The conjugation of amine-PEG-amine and anti-HER2 peptide with INDs followed a 
standard carbodiimide-mediated coupling procedure [40, 41]. Briefly, 2 mg of INDs were 
dissolved in 2 mL of sodium borate buffer (10 mM, pH 8.5), followed by sonication 
(Sonicator FS110, Fisher Scientific) for 30 min. EDC•HCl (4 mg) and NHS (4 mg) were 
added to the IND solution, which was stirred at room temperature (ca. 20 °C) for 0.5 hr to 
form the amine-reactive IND intermediates prior to addition of a 0.5-mL solution of amine-
PEG2000-amine (10 mg). After stirring overnight, the amine-PEG-INDs were purified by 
centrifugation at 10,000 × g for 5 min, and the precipitate was washed three times with DI 
water. To synthesize the HER2-PEG-INDs, the carboxyl terminus of the anti-HER2 peptide 
(1 mg) was pre-activated by mixing with EDC•HCl (4 mg) and NHS (4 mg) for 0.5 hr in DI 
water, followed by addition of the amine-PEG-IND (2 mg) aqueous solution. The mixture 
was stirred for 18 hr and the resulting nanoparticles were separated from the solution by 
centrifugation, washed with DI water three times, and dried in a SpeedVap (Labconco).
Characteristic peaks in Fourier-transform infrared spectra (IRAffinity-1 FTIR 
Spectrophotometer, Shimazu) confirmed the coating of PEG and anti-HER2 peptide on the 
INDs. Hydrodynamic diameters and zeta potentials of IND particles in aqueous solution 
were determined using a ZetaPALS (Brookhaven Instrument Corporation). All 
measurements were carried out with five replicates. The morphology of INDs was 
determined with high-resolution Transmission Electron Microscopy (TEM) (FEI Tecnai F20 
XT Field Emission TEM) using a lacey carbon coated copper grid (TED PELLA, Redding, 
CA).
Optical absorption spectra of INDs suspended in DI water (1 mg/mL) were measured at 
room temperature by using a UV-Vis spectrophotometer (U-3310, Hitachi) in a glass cuvette 
with an optical path of 10 mm. Un-irradiated NDs were used as the reference. The optical 
characterization of the INDs was performed using the same PA setup as described in our 
previous study [42]. A DI water suspension of INDs was injected into Tygon tubing (1 mm 
ID, 1.78 mm OD), which was immersed in water. The PA amplitude of INDs at different 
wavelengths was recorded with five replicates.
2.3 Cell Culture and In Vitro Cytotoxicity
Murine mammary tumor 4T1.2 is known for its highly metastatic pattern, which mimics 
closely to that of human breast cancer. 4T1.2-neu was established by the transformation of 
4T1.2 to express oncogene HER2/Neu [43]. The 4T1.2 and 4T1.2-neu breast cancer cells 
were cultured in DMEM containing 10% FBS and 1% L-glutamine at 37 °C supplied with 
5% CO2 under a humidified environment. The 4T1.2-neu cells (5000/well) were seeded onto 
96-well plates in 100 μL of culture media and incubated for 24 hr. HER2-PEG-INDs in 10 
μL of PBS were added at a series of final concentrations (10, 50, 100, 150 and 200 μg/mL). 
After incubation for 48 h, the cell viability was evaluated by the Resazurin-blue assay.
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2.4 Cellular Uptake and Imaging
To quantify the cellular uptake of INDs and image nanoparticles inside the cells, INDs, 
PEG-INDs and HER-PEG-INDs were labeled with a fluorescent dye. Briefly, 500 μg of 
PEG-INDs or HER2-PEG-INDs were dissolved in 500 μL of sodium borate buffer (10 mM, 
pH 8.5), followed by the addition of Cyanine7 (Cy7) NHS ester (100 μg in 10 μL of 
DMSO). The mixture was stirred overnight at room temperature in the dark and the resulting 
nanoparticles were separated from the solution by centrifuge, washed with DI water/ethanol 
(v/v, 1:1) three times and dried in a SpeedVap concentrator (Labconco Corp.). To determine 
the cellular uptake of PEG-INDs and HER2-PEG-INDs, cells were seeded onto 12-well 
plates at a density of 25 × 104 and incubated for 24 hr. 4T1.2-neu cells were treated with 
Cy7-PEG-INDs or Cy7-HER2-PEG-INDs at a final concentration of 5 μg/mL (based on 
INDs), whereas 4T1.2 cells were treated with Cy7-HER2-PEG-INDs at a final concentration 
of 5 μg/mL (based on INDs) followed by incubation at 37 °C for 6 hr. Then the cells were 
washed three times with 3 mL of PBS and removed after incubation with 50 μL lysis buffer 
[5 mmol/L EDTA, 10 mmol/L NaOH, 10 mmol/L Tris base, 150 mmol/L NaCl and 1% 
(v/v) Triton X-100] for 10 min at room temperature. Another 450 μL of DI water was added 
to each well, and the fluorescence intensity of the resulting cell lysate samples were 
analyzed based on a standard curve of free Cy7 NHS ester solution prepared in 1:3 (v/v) 
lysis buffer/DI water. The cell protein content was quantified using a Pierce™ BCA protein 
assay (Thermo Scientific). For the HER2 competitive inhibition experiments, cells were 
exposed to anti-HER2 peptide (0.75 μg/mL) for 1 h before the incubation with Cy7-PEG-
INDs or Cy7-HER2-PEG-INDs (10 μg/mL based on INDs) for 3 hr. The cell lysis 
procedures and analysis methods were identical to the cellular uptake study.
Cells were seeded onto poly-L-lysine precoated glass coverslips (BD, Franklin Lakes, NJ) in 
12-well culture plates at a density of 50,000 cells per well and grown overnight. 4T1.2-neu 
cells were treated with or without 32 μg of PEG-INDs or HER2-PEG-INDs (based on 
INDs), whereas 4T1.2 cells were treated with or without 32 μg of HER2-PEG-INDs (based 
on INDs) followed by incubation at 37 °C for 4 hr. Then the cells were washed three times 
with 3 mL of PBS and imaged using an inverted microscope (Eclipse TE2000-U, Nikon).
2.4 Photoacoustic Imaging
The experimental setup for PA imaging of biological tissues has been described before [42, 
44]. The deep reflection-mode PA imaging system is capable of sub 0.2-mm resolution at 
depths of 19 mm and penetration of up to 38 mm [45]. A 532-nm Q-switched Nd:YAG laser 
(Surelite III, Continuum) pumped an optical parametric oscillator laser (Surelite OPO PLUS, 
Continuum) with 6-ns pulses at a repetition rate of 10 Hz, and an optical condenser 
transformed the laser output to a ring-shape illumination, which was confocal with the 
ultrasonic transducer in the targeted area. The illumination beam had a diameter of 7 mm on 
the tissue surface, and the laser fluence was 18 mJ/cm2, which was lower than laser safety 
limits (20 mJ/cm2) recommended by the American National Standards Institute (ANSI). A 
5-MHz transducer (35-mm focal length; 70% −6-dB fractional bandwidth, SU-108-013, 
Sonic Concepts) collected the photoacoustic signals, which were amplified by a pre-
amplifier (5072PR, Olympus-NDT) and then collected by a PC through an A/D scope card 
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(CS21G8-256MS, Gage) with 8-bit resolution and a 125-MHz sampling rate for forming and 
analyzing PA images using MATLAB® software (Mathworks, Natick, MA).
Animal studies used female BALB/c mice in accordance with an approved protocol under 
the guidance of the Institutional Animal Care and Use Committee at the University of 
Kansas. The murine breast cancer cells, 4T1.2 and 4T1.2-neu, were prepared in PBS at a 
concentration of 2 × 107 cells/mL, and were kept in an ice bath before injection. Mice were 
anesthetized with 1.5% isoflurane in 1:1 oxygen-air mixture, and a 50-μL cell suspension 
was injected subcutaneously into the right mammary fat pad under the second nipple and 
along the lateral line of the mice using a 30-ga needle. Mice were ready for PA imaging 
when the breast cancer tumors obtained dimensions of ca. 5 × 5 mm, as measured with a 
digital caliper.
Before each imaging experiment, the animals were anesthetized with a mixture of ketamine 
(87 mg/kg body weight) and xylazine (13 mg/kg body weight). The right breast areas of 
mice were depilated using surgical hair removal lotion to avoid the interference from hairs 
to ultrasound propagation. The mice were maintained under anesthesia on a warm pad and 
underneath the membrane in the center of the bottom of the water tank during the entire 
imaging process. Between the skin and the membrane, ultrasound gel was applied as a 
coupling medium. The breathing rate of mice was visually monitored and maintained at one 
breath per two seconds. PA images of the breast tumor areas were obtained as background 
images before injecting PEG-INDs or HER2-PEG-INDs particles. After determining the 
depth of the detector’s focal point (2 – 3 mm) along with the imaging resolution of ca. 270 
μm, particles were administrated intravenously via the tail vein. The tumor areas were 
scanned continuously and repeatedly at a rate of 20 min per scan at a laser wavelength of 
820 nm.
The signal intensity of the tumor area was measured using ImageJ software (v 1.46r, http://
imagej.nih.gov/ij/). PA images were converted to grayscale images, followed by the 
quantification of PA signal intensity of the tumor region by measuring the mean gray values 
(unit: gray/pixel). The extent of signal enhancement was calculated with the following 
equation: increase in PA signal = [(intensity of each time point - intensity of background 
image)/intensity of background image)] × 100%.
2.5 Hemolysis and Platelet Coagualtion Assay
Fresh rat whole blood from a female Sprague-Dawley rat was stabilized with EDTA. Serum 
was removed from the blood sample by centrifugation at 1200 × g for 5 min at room 
temperature, and the remaining red blood cells (RBCs) were washed 5 times with isotonic 
PBS and then diluted 10 times with the same solution after the last wash. Diluted RBCs 
suspension (0.02 mL, ca. 4 × 108 cells/mL) was added to the nanoparticle suspension (0.08 
mL) prepared with PBS at a concentration of 100 μg/mL. After vortexing, the mixtures were 
incubated at room temperature for 2 h, and then samples were centrifuged for 5 min at 1500 
× g to remove nanoparticles and intact RBCs. The absorbance of the hemoglobin in the 
supernatant at 570 nm was measured. Triton X-100 (1%) and PBS were used as positive and 
negative controls, respectively.
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Platelet aggregation was assessed by tracking changes in the particle size using a Coulter 
particle counter (Coulter Multisizer 4, Beckman Coulter, Pasadena, CA). Fresh rat whole 
blood was withdrawn and placed in heparinized tubes (BD Vacutainer® Lithium Heparin 37 
USP unit, BD Franklin Lakes, NJ). Blood was centrifuged at 150 × g for 15 min to obtain 
platelet-rich plasma (PRP). PRP was pretreated with ADP sodium salt (0.5 μM), PBS, or 
INDs (20, 50 and 100 μg/mL). The mixtures were incubated at 37 °C for 3 min. After 
dilution in Isoton II electrolyte (Coulter Electronics), particle sizes of platelet aggregates 
were measured using a 50-μm aperture tube.
2.6 Histopathological Examination
Animals were euthanized 12 hr after injection of INDs or saline, and the kidneys and livers 
were resected and fixed in 10% formalin. A blinded board-certified pathologist at Lawrence 
Memorial Hospital (Lawrence, KS) conducted pathological examinations; sections and recut 
sections of kidneys and livers in both groups were stained with hematoxylin and eosin (H & 
E) and microscopically examined.
2.6 Statistical Analysis
GraphPad Prism 5 software was used for statistical analysis. The difference between two 
data sets were analyzed using t-test, while a one-way ANOVA was used for analyzing the 
differences among experimental and control groups. In all comparisons, a p value of ≤ 0.05 
[marked with an asterisk (*) in figures] was considered to be statistically significant.
3. Results
3.1. Synthesis and Characterization
The TEM image of the bare INDs after radiation and acid treatment is presented in Figure 1. 
INDs exhibited quadrilateral shapes with an average diameter of ca. 38 nm.
For INDs irradiated by 40-keV He+ ions at a dose of ca. 3 × 1015 He+/cm2, our previous 
experiments have estimated that they contain an ensemble of vacancies with a density in the 
range of ca. 3000 ppm [39]. Creating vacancies in such a high density often results in 
amorphization of diamond as well as severe broadening of the optical absorption bands [46, 
47]. No distinct zero-phonon line corresponding to GR1, i.e. the isolated neutral vacancy 
center, could be detected at 741 nm [48]. Instead, the UV-Vis spectrum of the INDs shows a 
monotonic increase in absorbance from 850 to 450 nm (Figure 2), similar to those of carbon 
black and other carbon nanomaterials [49]. PA signal amplitude showed a similar decreasing 
trend from 680 nm to 900 nm.
Since photoacoustic imaging is an absorption-based technology, the PA signal amplitude 
decreased in proportion to the decline of the optical absorption in the tunable wavelength 
range of the PA imaging system. Although the small bump at 720 nm in the PA spectrum is 
not shown in the UV-Vis absorption spectrum, the signal intensity dropped 50% from 700 
nm to 840 nm, which was the same trend as the absorption spectrum. The tumor areas of 
mice bearing breast cancer were imaged at 820 nm. Although INDs had stronger absorption 
and thus higher contrast against background tissues at 700 nm comparing to 820 nm, the 
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signal contributions from blood vessel would also be greater [50]. An imaging wavelength 
of 820 nm was chosen for in vivo studies because the absorption of hemoglobin and Mie 
scattering is minimized, and the PA signal enhancement is more pronounced in the images 
due to the accumulation of IND particles.
Conjugation of amine-PEG-amine (MW 2000) and anti-HER2 targeting peptide to the INDs 
was verified by FTIR (Figure 3). The appearance of the characteristic peaks of the PEG, at 
1250 and 1035 cm−1, confirmed the presence of the coating on the surface of bare INDs. In 
addition, the FTIR spectrum of HER2-PEG-INDs displayed the same intense peaks as anti-
HER2 peptide at 1656 and 1521 cm−1, corresponding to the stretching vibration of the 
amino group on lysine and hydroxyl group on tyrosine, respectively. The band at 1200–1260 
cm−1 resulted from the -OH stretching vibration in the serine.
In addition to the FTIR spectra, the coating of PEG and HER2 targeting peptide was further 
confirmed by the hydrodynamic diameters and zeta potentials of the INDs and the surface-
functionalized INDs. Table 1 shows the progressive increase in particle size and decrease in 
negative charge of the nanoparticle surfaces. The decrease in the negative charges was due 
to the introduction of amino groups from amine-PEG-amino and lysine residues in the anti-
HER2 peptides.
Both FTIR spectra and increased particle sizes are consistent with the introduction of HER2 
targeting peptide onto the INDs via the linkage to amine-PEG-amine. We assumed ca. 10% 
of the carboxyl groups on the INDs were reacted with amine-PEG-amine, which was 
described similarly before, and that amino group on INDs were conjugated with anti-HER2 
peptide in a 1:1:1 ratio. Consequently, yield for the amount of targeting peptide on the 
surface of INDs was expected to be ca. 10−5 mol/g[51]. Using UV-absorbance, the labeling 
was determined to be ca. 8.6 × 10−5 moles of HER2 targeting peptide per gram of PEG-IND 
nanoparticles (see Supporting Information).
3.2 Cytotoxicity, Cellular Uptake and Cellular Imaging
In order to evaluate the cytotoxicity of HER2-PEG-INDs and the potential for biological 
applications, 4T1.2-neu cells were incubated with particles for 48 h at concentrations 
ranging from 10 to 200 μg/mL. As shown in Figure 4, there was a dose-dependent decrease 
in cell viability above 10 μg/mL, and the cells retained viability up to 90% at concentrations 
of 10 and 50 μg/mL after 48 h. However, a reduction in cell viability was observed at higher 
concentrations.
The targeting ability of anti-HER2-peptide to HER-overexpressing breast cancer cells was 
evaluated by measuring the intracellular fluorescence intensity after treatment of HER2-
positive and –negative cells with Cy7-labeled INDs. In Figure 5a, significantly increased 
cellular accumulation of HER2-PEG-INDs by 4T1.2-neu cells was observed. This result can 
be explained by that HER2-PEG-INDs was taken up via HER2 receptor mediated 
endocytosis. Thus, a competitive inhition assay was performed to confirm the target-specific 
uptake behavior of anti-HER2 peptide conjugated INDs. Not surprisingly, remarkly 
suppressed internalization of HER-PEG-INDs by 4T1.2-neu cells was found as anti-HER2 
peptide (0.75 μg/mL) was added to the media 1 hr before the addition of INDs (Figure 5b). 
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This result suggested that the uptake of HER2-PEG-INDs was hindered effectively by 
reducing the availability of HER2 receptors on the surface of 4T1.2-neu tumor cells. In 
contrast, the internalization of PEG-INDs by 4T1.2-neu cells and HER2-PEG-INDs by 
4T1.2 cells remained unaffected in the presence of anti-HER2 peptide.
The cellular uptake anti-HER2 peptide was confirmed in vitro by the brightfield images of 
INDs interactions with HER2 receptor positive and negative breast cancer cells (4T1.2-neu 
and 4T1.2 cells) (Figure 6). As negative controls, 4T1.2-neu breast cancer cells were treated 
with non-targeted PEGylated INDs (4T1.2-neu cells + PEG-INDs) and HER2 negative 
4T1.2 cells were treated with targeted PEGylated INDs (4T1.2 cells + HER2-PEG-INDs). 
The clusters of IND particles present black spots in the cells. There was no obvious 
accumulation of INDs in the control groups after 4 hr of incubation (Figure 6b and 6d). By 
contrast, HER2-PEG-INDs, which contain the HER2 targeting peptide, accumulated to a 
greater degree inside cells and on the cell membranes (Figure 6e). This indicated that the 
HER2-specific peptide increased the cellular uptake of HER2-PEG-INDs by HER2 over-
expressing cells. This result was further confirmed by comparing the fluorescence images of 
breast cancer cells incubated with Cy7 labeled INDs (Supporting Informations Figure S2). 
The amount of HER2-PEG-INDs internalized by HER2-overexpressing cells was apparently 
larger than that of INDs internalized by cells without targeting effect.
3.3 In Vivo PA Imaging
Prior to the injection, a region of interest (ROI) was selected on the right side of the breast 
and defined as background (BG). The depth of the detector’s focal point was adjusted so as 
to obtain the best spatial resolution. BALB/C mice were injected with identical amounts of 
INDs via the tail vein. Once the depth of the detector’s focal point was determined, PA 
images of the same areas were taken with 1-hr intervals and processed to remove the skin’s 
signal as illustrated in Figure 7. The three control groups were the HER2 positive tumor 
model (4T1.2-neu) treated with saline (Figure 7a), HER2 positive tumor model (4T1.2-neu) 
treated with PEG-INDs (Figure 7b) and the HER2 negative tumor model (4T1.2) treated 
with HER2-PEG-INDs (Figure 7c). In the PA images, the blood vessels (BVs) were 
highlighted because of the relatively higher optical absorption of hemoglobin over normal 
optically transparent tissues. Signal intensity did not significantly increase in the saline 
group until 8 hrs post-injection (Figure 7a). Beginning at 2 hrs post-injection, the blood 
contrast was enhanced as indicated by the colorbars in the figures, and signal intensity 
peaked at 4 to 6 hrs in each group. Meanwhile, IND particles progressively migrated from 
the blood vessels into internal tumor regions, presumably due to the enhanced permeability 
and retention (EPR) effect and retention by the HER2-positive cancer cells. The HER2-
positive breast cancer model treated with HER2-PEG-INDs had higher signal enhancement 
around the tumor region that finally delineated the entire tumor (dashed circle in Figure 7d) 
at 8 hrs, compared to the HER2-negative tumors and untargeted INDs in the HER2 positive 
tumors (Figure 7e).
The hemolytic activity of INDs was conducted by a colorimetic assay of the iron-containing 
protein hemoglobin released by damaged cells upon exposure to INDs. As shown in Figure 
8a, all INDs did not induce RBC destruction at the concentration as high as 100 μg/mL. In 
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order to further investigate the hematocompatibility of INDs, platelet aggregation behavior 
was performed by incubating INDs with PRP at 37 °C for 3 min and measuring the averaged 
particle sizes of platelet aggregates. Compared to the positive and negative controls (Figure 
8b), the average particle size did not significantly change at the highest concentrations tested 
(100 μg/mL). In addition, no platelet aggragation was induced by INDs at lower 
concentrations (data not shown). Furthermore, the hematology biocompatibility of INDs 
with mice was assessed by measuring the hematological parameters, including leukocytes, 
lymphocytes, erythrocytes and mean hemoglubin, and biomakers of liver damage, aspartate 
aminotransferase (AST) and alanine aminotransferase (ALT). The results in Table S1 
showed that there were no significant changes in these parameter values and thus no 
significant inflammation induced after exposure to HER2-PEG-INDs, compared to saline.
3.4 Histopathological Examination
No significant histopathological abnormalities were observed in the kidneys nor livers of 
mice injected with INDs compared to saline injected mice, and no inflammation was 
observed by H&E staining (Figure 9 and Figure S3), which demonstrated no apparent 
toxicity of these INDs to the renal and hepatic organs at 12 hr after i.v. administration.
4. Discussion
The HER2 receptor is overexpressed in 25% to 30% breast cancers and has been exploited 
as a molecular target for delivery of drugs and nanoparticles for biomedical applications [52, 
53]. The HER2-targeting peptide (KCCYSL) is relatively small, but it exhibited high 
affinity (295 ± 56 nmol/L) to the HER2 receptor [37]. Due to its small size, this anti-HER2 
peptide can be conjugated to the surface of nanoparticles with higher density in comparison 
to larger HER2-targeting antibodies. As a result, cellular uptake was enhanced leading to 
rapid entrance of nanoparticles into the tumor cells. In addition, the peptide-targeting moiety 
may have less immunogenicity and cytotoxicity than antibody-based ones because of its 
lower molecular weight [54]. Uptake of the peptide-nanoparticle conjugate in 4T1.2-neu 
breast cancer cells was appreciably higher than that of PEGylated INDs (Figure 5a). 
Meanwhile, owing to the specific binding of HER2-PEG-INDs to the tumor, the 
nanoparticle clearance rate from blood circulation was decreased and the loss of 
nanoparticles was minimized (Figure S2) [55]. For this reason, limited accumulation and 
rapid clearance of non-targeted INDs in the control groups made it difficult to differentiate 
the tumor regions in PA images. Whereas, the tumors in mice treated with HER-PEG-INDs 
were fully delineated by strong contrast between the tumor regions and surrounding tissues. 
This result is further confirmed by the prolonged retention time within tumors in the HER2 
targeted treatment group. The prolonged presence of contrast agent in the tumor is critical 
for PA assisted cancer detection. So, the signal intensity of the tumor region was monitored 
and compared between two consecutive scans until a decrease in signal amplitude was 
observed. The maximum accumulation of HER2-PEG-INDs in HER-overexpressing tumor 
bearing mice was at 8 hrs post-injection, contrasted with 6 hrs in the control groups (Figure 
10, p < 0.05, n = 3). Furthermore, the HER2-PEG-INDs had a more rapid uptake and a 
relatively slower clearance rate in the HER2-positive tumor model. The PA signal was 
significantly enhanced in the HER2-positive tumor region after 2 hrs (Figure 7e), and there 
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was no evidence of a signal decrease until 11 hrs post-injection (Figure 7d). However, in the 
HER2-negative and non-targeted control groups, PA amplitude increased slowly and then 
declined rapidly within one hour (Figure 7b and 7c). Since the rate of extravasation from the 
poorly formed blood vessels into the tumor region and the rate of clearance are two major 
factors that affect the nanoparticle accumulation in the tumor, strong binding between the 
HER2-targeting peptide and HER2 receptor on the cell surface may favor the retention of 
HER2-PEG-INDs. Thus, even though PEG-INDs and HER2-PEG-INDs may have a similar 
opportunity to leak from the blood vessels due to the EPR effect, the differences in such 
factors as retention and cellular uptake resulted in quite different tumor accumulations of 
INDs and thus the accumulative PA signal enhancement.
Owing to the EPR effect, nano-sized particles or macromolecules administrated 
intravenously escape renal clearance and tend to leak out from the abnormal vasculature and 
accumulate in solid tumors [56]. However, Li M.L. etc demonstrated that gold nanoshells 
could not actually enter the necrotic tissues of tumor but accumulated within the tumor 
cortex, and the nanoshells delineated the tumor margins when imaged by PA microscopy at 
a wavelength of 800 nm [57]. The absence of INDs within the tumor core can be explained 
by both the necrotic feature and high interstitial pressure of tumor cores [58]. In addition, the 
observation of no INDs on the top surface of the tumor may be explained by the pressure 
from the water tank above the tumor area, which may hinder the circulation and particle 
accumulation.
Among carbon-based nanomaterials, NDs are considered to be less toxic than carbon 
nanotubes and graphene oxide [59]. This is mainly because of diamond’s unique properties 
of sp3 electron configuration, chemical inertness and especially due to the purification 
process in strong acid used to remove impurities and graphitic surface layers [24]. It has 
been demonstrated that carboxylated NDs internalized by macropinocytosis and endocytosis 
pathways did not show noticeable cytotoxicity or affect cell proliferation and differentiation 
[60], which was also indicated by our cytotoxicity study (Figure 4). In vivo biodistribution 
of NDs has been studied by positron emission tomography after labeling nanoparticles 
with 18F. The lungs, spleen and liver were the primary accumulating locations of NDs, and 
particles were excreted in urine beginning at 2 hr after i.v. administration [61]. On the basis 
of this study, we collected the kidneys, lung and liver 12 hr after injection of HER2-PEG-
INDs for histopathological examination, and we did not observe any indications of toxicity 
(Figure S3). This is consistent with other reports of the in vivo biocompatibility of NDs after 
multiple routes of administration [62, 63]. In addition, the long-term biocompatibility of 
INDs 12 weeks after intraperitoneal injection has been demonstrated by our group in a prior 
report [26]. Although the toxicity of these HER2-PEG-INDs needs to be systematically 
investigated and analyzed comprehensively before application in the clinic, our results have 
shown the biocompatibility and potential utility of HER2-targeting INDs for biomedical 
applications.
5. Conclusions
In this work, non-toxic, stable and targeted non-fluorescent INDs were successfully 
developed as a novel in vivo PA imaging contrast agent and shown to facilitate the optical 
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contrast enhancement of breast tumor margins. The conjugation of PEGylated INDs with 
anti-HER2 peptide lead to an enhancement in the internalization by HER2 overexpressing 
tumor cells (4T1.2-neu) and longer residence time in the region of HER2 positive tumor. We 
expect this targeted IND-PA imaging platform to provide a new oppotunity for sensitive 
phenotype specific detection of tumors.
6. Futher perspective
With the outstanding advantages of high optical absorption, photostability and 
biocompatibility, targeted IND conjugates can be used as a molecularly selective contrast 
agent for photoacoustic detection of cancers. The HER2 targeting peptide significantly 
improved the efficiency and specificity of delivery of INDs to HER2-positive breast tumors. 
It is expected that HER2-targed INDs may offer an effective means for early detection of 
HER2-positive breast cancers.
7. Executive summary
Preparation of human epidermal growth factor receptor-2 (HER2)-PEG-irradiated 
nanodiamonds (INDs)
• The HER2-PEG-INDs were designed to serve as a molecularly-targeted 
photoacoustic (PA) contrast agent for detection of HER2-positive breast cancer.
Cellular uptake of HER2-PEG-INDs by the HER2-positive tumor cells
• When conjugated with HER2-specific peptide, the internalization of INDs by HER-
positive cells was significantly increased compared to control groups.
Photoacoustic imaging of breast tumor
• The entire breast tumor area was completely delineated by the enhanced PA signal 
due to the accumulation of HER2-PEG-INDs in the HER-positive tumor model 
after i.v. injection.
Histopathological examination for toxicity
• 12 hr after i.v. administration of INDs, no apparent histopathological abnormalities 
nor inflammation were observed in the kidneys or livers of mice.
Conclusion
• The author’s study has demonstrated the first use of non-toxic INDs for phenotype 
detection and delineation of tumors.
• The HER2-targeting peptide resulted in improved tumor uptake and longer 
residence time of INDs in the tumor region, and thus enhanced the PA imaging 
contrast.
• This targeted-nanodiamond-PA imaging platform has potential as a more effective 
alternative to biopsy and nuclear imaging for sensitive detection of cancers.
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TEM image of INDs.
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Optical characteristics of INDs suspended in DI water as a function of wavelength.
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Infrared spectra of IND, PEGylated INDs (PEG-INDs), HER2-PEGylated INDs (HER2-
PEG-INDs) and anti-HER2 peptide.
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Cytotoxicity evaluation on 4T1.2-neu cells after 48 h of incubation with HER2-PEG-INDs.
Zhang et al. Page 20














Cellular uptake of INDs by 4T1.2 or 4T1.2-neu breast cencer cells without (a) and with (b) 
0.75 μg/mL anti-HER2 peptide pretreatment (* p < 0.05).
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Brightfield images of murine breast cancer cells. (a) Non-treated 4T1.2-neu cells, (b) 4T1.2-
neu cells treated with PEG-INDs, (c) Non-treated 4T1.2 cells, (d) 4T1.2 cells treated with 
HER2-PEG-INDs and (e) 4T1.2-neu cells treated with HER2-PEG-INDs. Scale bars 
represent 10 μm in length.
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PA images of ROI before and at different time points after the injection of saline or INDs 
and photographs of ROI. a) 4T1.2-neu tumor model injected with saline, b) 4T1.2-neu tumor 
model injected with PEG-INDs, c) 4T1.2 tumor model injected with HER2-PEG-INDs, d) 
4T1.2-neu tumor model injected with HER2-PEG-INDs, e) increase in PA amplitude of 
tumor areas plotted as time post-injection (n=3, p < 0.05, * p < 0.05, ** p < 0.01).
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Hemolysis and platelet coagulation studies of INDs with rat RBCs and PRP. a) hemolysis 
percentages measured for INDs incubated with RBCs at a concentration of 100 μg/mL, and 
b) Partical size of platelet aggregates measured for INDs incubated with PRP at a 
concentration of 100 μg/mL. The experiments were repeated in triplate (*** p < 0.001; ns, p 
> 0.5).
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Representative H&E stained images of kidneys and livers collected from saline injected 
mice and HER2-PEG-INDs injected mice at 12 hr post-injection.
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Nanoparticle retention time in PA imaging groups (* p < 0.05; ns, p > 0.05).
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Table 1
Particle sizes and zeta-potentials of INDs, PEGylated INDs and HER2 targeting peptide conjugated PEG-
INDs.
Particles Diameter (nm) Zeta-potentials (mV)
INDs 38.3 ± 0.0 −36.49 ± 1.27
PEG-INDs 56.0 ± 0.1 −33.07 ± 1.44
HER2-PEG-INDs 92.1 ± 1.1 −22.67 ± 1.07
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